🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “The First People's Hospital of Lianyungang” Clear

  1. 68Ga-NOTA-MAL-Cys39-exendin-4

    The First People's Hospital of Lianyungang

    Insulinoma

    phase 1 small molecule active

    1 trial

  2. 68Ga-PSMA-11

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  3. 68Ga-Pentixafor

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 1 small molecule active

    1 trial

  4. 99mTc-QULIC-5-P1

    The First People's Hospital of Lianyungang

    Prostate Cancer Stage

    phase 1 small molecule active

    1 trial

  5. A-CAR028

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 1 mab active

    1 trial

  6. AFN50 injection

    The First People's Hospital of Lianyungang

    Autoimmune Diseases

    phase 1 mab active

    1 trial

  7. ATHENA CAR-T

    The First People's Hospital of Lianyungang

    Lupus Erythematosus, Systemic

    phase 1 mab active

    1 trial

  8. Adebrelimab

    The First People's Hospital of Lianyungang

    Biliary Tract Malignancies

    phase 1 small molecule active

    1 trial

  9. Akk Gut Bacteria Supplement

    The First People's Hospital of Lianyungang

    Premature Ovarian Failure (POF)

    phase 1 other active

    1 trial

  10. All-trans retinoic acid

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  11. Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）

    The First People's Hospital of Lianyungang

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  12. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  13. Anti-BCMA CAR-T cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  14. Anti-CD19-CAR

    The First People's Hospital of Lianyungang

    Leukemia

    phase 1 mab active

    1 trial

  15. Anti-CD20 monoclonal antibody and the BTK inhibitor

    The First People's Hospital of Lianyungang

    Anti-CD20 Monoclonal Antibody

    phase 1 small molecule active

    1 trial

  16. BAO-G

    The First People's Hospital of Lianyungang

    Thoracoabdominal Aortic Aneurysm

    phase 1 other active

    1 trial

  17. Biological: LV009 injection

    The First People's Hospital of Lianyungang

    CD19+ Relapse/Refractory B-ALL

    phase 1 small molecule active

    1 trial

  18. CAR-BCMA T cells

    The First People's Hospital of Lianyungang

    Refractory or Relapsed Multiple Myeloma

    phase 1 gene therapy active

    1 trial

  19. CAR-T cell infusion

    The First People's Hospital of Lianyungang

    Hematolymphoid Malignancies

    phase 1 small molecule active

    1 trial

  20. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  21. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  22. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  23. CD19 and BCMA-targeted allogeneic CAR-T cells

    The First People's Hospital of Lianyungang

    Refractory Immune-mediated Platelet Transfusion Refractoriness

    phase 1 gene therapy active

    1 trial

  24. CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

    The First People's Hospital of Lianyungang

    Refractory Idiopathic Membranous Nephropathy

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources